Author Archive: Roy Zwahlen

Roy Zwahlen

Roy is Associate Counsel at BIO and the main contributor for Patently Biotech. He is a lawyer by training, with a background in international and national politics. He grew up in the developing world and believes that innovation can and does solve many of the world’s problems. Because of this, his work focuses on creating a worldwide policy environment that fosters innovation in the biotechnology sector to prevent and cure diseases such as HIV, to increase crop yields to feed more people, and to decrease the harmful effects of industry on the environment. Roy spends his free time keeping up with his three kids, a wife that knows everything (no joke), and serving in his church and broader community. Learn more about Roy from his Linkedin Profile.

Latest Posts

U.S. House passes Bayh-Dole 30th Anniversary Concurrent Resolution

On November 15th, the United States House of Representatives voted 385-1 for the Bayh-Dole 30th Anniversary Concurrent Resolution.   Here are some interesting quotes from the Resolution on the need for and the successes of Bayh-Dole. “the United States Government is one of the largest funders of research in the world, but that research does not fully benefit American taxpayers unless it contributes new products and processes to the marketplace, thereby creating new companies and jobs, and solving societal Read More >

Patently BIOtech  |  1 Comment  |  Email This Post
Tags: , , , , , , , ,

Is the Myriad Case Decision and/or the DOJ Brief TRIPS Compliant?

Judge Sweet seemed to dismiss Myriad’s constitutional taking and TRIPS claims by indicating: “Finally, Myriad’s suggestion that invalidating the patents-in-suit would constitute an unconstitutional taking in violation of the Fifth Amendment of the Constitution or a violation of the United States’ obligations under the Agreement on Trade-Related Aspects of Intellectual Property Rights (“TRIPS”) is unpersuasive. Myriad’s novel taking argument runs counter to a long history of invalidation of patent claims by the courts and is unsupported by legal Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , , , , , , ,

BIO’s Comments on proposed PTO Humanitarian Technologies and Licensing Through the Intellectual Property System

Here are the highlights from BIO’s recent submission on the proposed PTO “Request for Comments on Incentivizing Humanitarian Technologies and Licensing Through the Intellectual Property System.”   Background: 1.  “BIO’s members also understand that problems with access to medicines and other biotechnology products in the developing world have very little to do with the patent system, and are generally caused by other factors outside the control of individual stakeholders, such as lack of adequate local manufacturing, Read More >

Patently BIOtech  |  1 Comment  |  Email This Post
Tags: , , , , , , , , , , , , , , , , , , , ,

Recent Federal Register Notices

 A collection of Federal Register Notices dating back to November 5th.  Mainly for Small and Medium sized Enterprises: (SME) Government Programs to Assist Businesses Protect Their Intellectual Property Rights (IPR) in Foreign Markets; Notice of Extension of Comment Period PTO Proposed Rule: Rules of Practice Before the Board of Patent Appeals and Interferences in Ex Parte Appeals PTO Notice: Expansion and Extension of the Green Technology Pilot Program

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , ,

AUTM Bayh-Dole 30th Anniversary Event

Association of University Technology Managers Press Release Deerfield, IL — December 12, 2010 will mark the 30th anniversary of the Bayh-Dole Act. This legislation changed fundamentally the way America develops technologies from federally funded university research and effectively secured the country’s leadership position in innovation. As a result of Bayh-Dole, more than 6,000 new U.S. companies formed from university technologies, approximately 5,000 new products are on the market, 153 new drugs, vaccines or in vitro Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , ,